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Abstract
Background: Several preprocessing algorithms for Affymetrix gene expression microarrays have been developed, and their
performance on spike-in data sets has been evaluated previously. However, a comprehensive comparison of preprocessing
algorithms on samples taken under research conditions has not been performed.
Methodology/Principal Findings: We used TaqMan RT-PCR arrays as a reference to evaluate the accuracy of expression
values from Affymetrix microarrays in two experimental data sets: one comprising 84 genes in 36 colon biopsies, and the
other comprising 75 genes in 29 cancer cell lines. We evaluated consistency using the Pearson correlation between
measurements obtained on the two platforms. Also, we introduce the log-ratio discrepancy as a more relevant measure of
discordance between gene expression platforms. Of nine preprocessing algorithms tested, PLIER+16 produced expression
values that were most consistent with RT-PCR measurements, although the difference in performance between most of the
algorithms was not statistically significant.
Conclusions/Significance: Our results support the choice of PLIER+16 for the preprocessing of clinical Affymetrix microarray
data. However, other algorithms performed similarly and are probably also good choices.
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Introduction
Preprocessing of raw probe intensities is an essential procedure
in the analysis of gene expression microarray data. Generally,
background correction and normalization are used to reduce the
impact of variations in experimental conditions. Arrays featuring
multiple probes per gene target (such as those from Affymetrix)
require an additional probe-level summarization step to integrate
intensities of the multiple probes into a single expression estimate.
These steps involving background correction, normalization, and
summarization are often combined into a single all-in-one
preprocessing algorithm that takes raw probe intensities as input
and produces gene expression estimates as output. Several such
algorithms have been proposed, each based on a different model
or set of underlying assumptions. Because the choice of algorithm
can affect the conclusions drawn from the data, it is important to
compare the accuracy of these algorithms.
The performance of preprocessing algorithms has been
characterized in several ways, often with the help of data sets
created expressly for this purpose (evaluative data sets). For example,
the Latin square spike-in data sets from Affymetrix are derived
from composite RNA samples, in which a small number of
exogenous RNA species are added at various concentrations to a
fixed background. Here, the known concentrations of the
exogenous genes can be used as a reference to evaluate the
accuracy of the microarray expression values [1,2]. In another
approach, mixture experiments involve two or more biological
samples combined in various ratios, such that many genes are
differentially expressed and the linearity of response can be
quantified [3]. Such data sets have been the basis for systematic
comparison of preprocessing methods [4,5]. However, these data
sets were generated under well-controlled conditions with
relatively little variation in experimental or technical conditions
from sample to sample. In this way, these data are not
representative of typical microarray experiments performed in a
research setting, such as those involving clinical samples [6,7].
Therefore, it is also important to evaluate the performance of
preprocessing algorithms on microarray data created to address
biological or clinical research questions (investigational data sets) [7,8].
In such data, there are no gold standards to use to directly assess
accuracy. Instead, the relative performance of preprocessing
algorithms can be assessed using independent measurements,
such as a second microarray platform or quantitative real-time
PCR (RT-PCR) [9,10]. Unfortunately, only a few algorithms have
been compared in this manner, and the data is not publicly
available.
Here, we aimed to compare Affymetrix preprocessing algo-
rithms using data sets that are representative of our research. We
selected two investigational data sets, each featuring a relatively
large number of matched measurements by Affymetrix micro-
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arrays and RT-PCR, and used these data sets to compare the
accuracy of nine published preprocessing algorithms.
Results
Two representative investigational data sets
We chose to analyze two of our recently published data sets in
which RNA samples had been profiled both on gene expression
microarrays (Affymetrix) and on 96-well RT-PCR arrays (Taq-
Man). The first data set comprises 36 colon biopsies [11], and the
second comprises 29 cancer cell lines grown in vitro [12]. All data
was generated for previously published studies, without consider-
ation for its present use in this study of preprocessing algorithms.
Using current manufacturer-supplied annotations, we selected 84
probe sets in the colon cancer data set and 75 probe sets in the cell
line data set for which we had comparable RT-PCR measure-
ments (i.e. detecting the same set of transcripts). Evaluation of
consistency between the two platforms was restricted to these
matched measurements, which we call ‘‘genes’’ even though some
splice isoforms may not be detected.
To assess whether these two data sets were representative of
typical clinical data sets, we utilized three ‘‘bias metrics’’ as
indicators of technical variation [13]. These bias metrics, which
are calculated from the raw probe intensities, correspond to
technical aspects of the experiment, such as hybridization
conditions or RNA quality. In general, the expression values of
many genes are correlated with these bias metrics [13]. Thus, the
variation in bias metrics is an estimate of one type of noise that we
expected to be higher in clinical data sets than in spike-in data sets.
We compared the variation in bias metrics among several data
sets: the two data sets analyzed in this paper, two Latin square
spike-in data sets, and five tumor data sets that are relevant to our
research interests [14–18]. We found that the colon and cell line
data sets analyzed in this study are comparable to the tumor data
sets, whereas the spike-in data sets exhibited much lower variation
in the bias metrics (Figure 1). Thus, by this measure, the two data
sets analyzed in this study are representative of ‘‘typical’’ clinical
data sets, whereas the spike-in data sets are not.
Preprocessing algorithms
Several preprocessing algorithms for Affymetrix-type oligonu-
cleotide arrays have been proposed, but we evaluated only
algorithms that were published or referenced in peer-reviewed
journals and that were implemented in the R statistical
environment. We identified the following nine algorithms meeting
these criteria: DFW [19], FARMS [20], GCRMA [21], MAS5
[22], MBEI [23], PLIER [24], RMA [25], and VSN [26]. Two of
these algorithms, MBEI and PLIER, were not implemented in R
by the original authors, so we used published implementations of
these algorithms [27,28]. Although all of these algorithms have
adjustable parameters, we generally used the default parameter
values. As an exception, alternative parameter values for PLIER
were chosen by the manufacturer for use in a large evaluative
study, so we evaluated these settings (PLIER+16) in addition to the
defaults [3]. By evaluating only previously published parameter
values, we avoided problems of selection bias or overfitting that
would result if we had tested additional parameter values.
Evaluation of consistency between platforms
To a first approximation, the measured probe intensity is
proportional to its target transcript concentration, but is also
affected by other factors such as probe sequence. Therefore, the
absolute expression of a single gene in a single sample is not
directly comparable between different gene expression platforms.
However, the relative expression of a gene between two samples
should be directly comparable, as long as the normalization factor
is comparable. Microarray data is often normalized globally,
meaning that the distribution of expression levels of all genes is
assumed to be constant in all samples. On the other hand, RT-
PCR data is often normalized using a small number (e.g., one) of
housekeeping genes that are assumed to be constant. For our
study, to make the normalization of the microarray and RT-PCR
data as similar as possible, we normalized each sample according
to the median expression value of the common genes. This
additional normalization step increased concordance in both data
sets (data not shown).
To assess concordance between the two platforms, we treated
each gene as an independent measurement. For each gene, we
calculated the Pearson correlation coefficient (PCC) between the
log2-transformed expression values as measured by microarray
and those measured by RT-PCR. We then compared the
distributions of PCCs obtained using the various preprocessing
algorithms (Figure 2). Using the median of the PCC distribution as
the criterion to choose the most accurate algorithm, FARMS was
the most accurate on the colon data set, while PLIER+16 was
most accurate in the cell line data set. In both data sets, the
Figure 1. The colon and cell line data sets are representative of clinical microarray data. For several Affymetrix data sets, box-and-
whiskers plots indicate the distribution of three bias metrics: a) RNA degradation slope, b) median perfect-match probe intensity, and c) fraction of
probe sets called present. A narrower distribution indicates greater consistency in technical conditions. LatinSquare133 and LatinSquare95 are spike-in
data sets produced by the microarray manufacturer [1]; Gyorffy_cells and Gyorffy_colon are the data sets analyzed in this paper [11,12]; the other five
are publicly-available clinical data sets [14–18].
doi:10.1371/journal.pone.0005645.g001
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difference between the majority of the algorithms was not
statistically significant (Figure 2).
However, the use of PCC as measurement of concordance can
be problematic for two important reasons. First, a gene that is
essentially unchanging often has low PCC due to random noise,
even if both platforms agree that the gene is unchanging. Second,
a gene can have high PCC even if the two platforms are highly
discordant in magnitude; for example, when one platform
experiences compression due to chemical saturation at higher
intensities.
We sought to define a second metric for cross-platform
comparison that more intuitively indicates the agreement or
disagreement between sets of measurements. In practice, we are
most interested in the extent to which a gene measured on the two
platforms has the same log ratio for a given pair of samples. Thus,
for each gene g we define the log-ratio discrepancy (LRD) as:
LRDg~
2
N N{1ð Þ
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i~1
XN
j~iz1
log2
xgi
xgj
 
{log2
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 
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where N is the number of samples, and xgs and ygs are the expression
values of gene g in sample s, as measured on each platform. In
simpler terms, the LRD of a gene is the absolute difference in log-
ratio as measured between platforms, averaged over all possible
pairs of samples. Therefore, the LRD has a minimum possible value
of zero (perfect agreement) and a maximum value limited only by
the dynamic range of the two platforms. An R script implementing
the LRD is available in Text S1.
We calculated the LRD between the microarray and RT-PCR
expression values for each gene and compared the LRD
distribution between the nine preprocessing algorithms (Figure 3).
Using the median of the LRD values as the criterion to choose the
best performing preprocessing algorithm, we found PLIER+16 at
the top of the list in both data sets. Again, several other algorithms
showed similar performance, and the difference between the top
few algorithms was not statistically significant (Figure 3).
Discussion
Several preprocessing algorithms have been proposed for
Affymetrix arrays, but so far it is unknown whether one particular
algorithm provides more accurate results. Several important studies
attempting to answer this question using artificially produced RNA
samples have been a key source of guidance for investigators [2,4].
Until now, there has been a lack of systematic comparisons of the
Figure 2. Pearson correlation coefficients between microarray and RT-PCR. The distribution of Pearson correlation coefficients for each
microarray preprocessing algorithm is indicated by a box plot, for a) the colon cancer data set (84 genes, 36 samples), and b) the cell line data set (75
genes, 29 samples). The box indicates the 25th to 75th percentile, and the heavier line indicates the median. Algorithms are displayed in decreasing
order of the median, such that the more accurate algorithms are at the top. The colorgrams on the right-hand side indicate P values (Wilcoxon test)
comparing each pair of algorithms.
doi:10.1371/journal.pone.0005645.g002
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performance of preprocessing algorithms in investigational studies. In
this study, we have evaluated nine preprocessing algorithms in two
complementary data sets that are representative of typical microarray
experiments that we generate and analyze in our research. Because
none of the true gene expression levels are known exactly, we assessed
the accuracy of the various preprocessing algorithms by comparing
the generated expression values with those measured independently
on RT-PCR arrays.
RT-PCR is often used to ‘‘confirm’’ microarray results because
of its relatively accurate measurements over a wide dynamic range.
However, the interpretation of these results can be problematic
because RT-PCR expression values can vary based on choice of
normalization controls [29]. Although our study has been designed
in a way to avoid standard housekeeping gene-based normaliza-
tion of RT-PCR data, this task is important for accurate results in
actual research situations. Despite the fact that no single gene is
expressed at a constant level in all biological samples, RT-PCR
measurements are often normalized to a single gene. Several
publications have introduced more rational normalization meth-
ods for RT-PCR. A model-based variance estimation approach
was introduced to identify genes with the lowest variance in a
given type of data set and therefore best suited for normalization
[30]. In another approach, the geometric average of multiple
control genes was found to be an accurate normalization factor for
RT-PCR measurements [29].
Although the accuracy of preprocessing algorithms for Affyme-
trix microarrays could be compared in numerous ways, we have
used two performance metrics. First, we used the PCC because it is
intuitive and because it gives a useful measure of concordance
under many conditions. Additionally, we introduced the log-ratio
discrepancy, which we believe is a more useful assessment of
expression value accuracy in the context of our biomarker research
due to its ability to take into consideration the impact of genes that
do not change their expression across the various samples in the
cohort. Researchers using microarrays for other types of
experiments may find other performance metrics to be more
relevant to their research, and our results should be considered in
this context. For example, the LRD penalizes compression-type
artifacts; whereas PCC does not. Such artifacts may be acceptable
for simple analysis such as searching for differentially expressed
genes between two relatively homogeneous groups. However, such
artifacts are not acceptable when the response must be linear, e.g.
in principal components analysis. An open question is whether the
optimal choice of preprocessing algorithm is dependent on the
type of data, or on the biological question being asked. For
example, some analysis, such as regulatory network reconstruc-
Figure 3. Log-ratio discrepancy between microarray and RT-PCR. The distribution of the log-ratio discrepancy for each microarray
preprocessing algorithm is indicated by a box plot, for a) the colon cancer data set, and b) the cell line data set. Algorithms are displayed in order of
the median, such that the more accurate algorithms are at the top. The colorgrams on the right-hand side indicate P values (Wilcoxon test)
comparing each pair of algorithms.
doi:10.1371/journal.pone.0005645.g003
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tion, may be highly sensitive to random correlations, in which case
concordance with RT-PCR measurements may not be the only
consideration for selecting an algorithm [13,31].
Naturally, our choice of data sets from colon biopsies and cancer
cell lines reflects our research interests. These data sets, like many
recent large-scale data sets, were generated using the HG-U133A or
HG-U133 Plus 2.0 microarrays, which use a 39-biased amplification
protocol and a transcript-based probe set design. In contrast, the
newer generation of microarrays from Affymetrix utilizes a whole-
transcript amplification protocol and an exon-based probe design,
which may offer a more specific portrait of expressed sequences
[32]. Preprocessing algorithms that perform well in the U133 arrays
should also perform well in the newer arrays, but it will be important
to confirm this as researchers adopt the newer platforms.
Several other studies have compared preprocessing algorithms
using different data sets and/or different metrics. Cope et al.
described a series of tests to evaluate preprocessing algorithms using
the spike-in data set from Affymetrix and the dilution data set from
Genelogic. They generally observed better performance fromRMA
and MAS5 than from dChip (MBEI), which is consistent with our
findings. Choe et al. generated a spike-in data set with a defined
background, in contrast to the Affymetrix spike-in data sets, which
use HeLa RNA as background [2]. Instead of comparing all-in-one
preprocessing algorithms as we did, they evaluated the relative merit
of the individual background correction, normalization, and
summarization steps. Dallas et al. compared Affymetrix arrays with
RT-PCR measurements of 48 genes in various human samples
using PCC as the performance metric [8]. They evaluated only
MAS5 and RMA and found that the two algorithms had
comparable performance. Qin et al. compared microarrays to
RT-PCR using mouse heart tissue and Pearson correlation of fold
change as a performance metric, and found that MAS5, dChip-
with-mismatch, and GCRMA outperformed dChip-without-mis-
match (analogous to our ‘‘MBEI’’), RMA, and VSN [7]. Barash et
al. used variability in redundant measurements to estimate noise,
and found that RMA outperformed dChip and MAS5 without
decreasing the number of differentially expressed genes [6]. There is
some disagreement between these results and ours, which might
stem from differences in data sets and methodology.
It is our impression that the most commonly used algorithms are
MAS5, MBEI, and RMA [33]. This may be partially due to their
relatively early availability (2001–2003) or partially due to their
packaging within relatively user-friendly software (MAS5 and
MBEI) or fast computation in R (RMA). Therefore, it is reassuring
that these three algorithms performed well in our tests, although
MBEI was slightly weaker. We were somewhat surprised by the
performance of the MAS5 algorithm, which has not always
performed well in earlier comparisons [21,25]. Notably, MAS5 is
the only algorithm in our comparison that operates on a single
array at a time, a feature that is advantageous for diagnostic use
but may represent a handicap compared to the other algorithms,
which theoretically gain accuracy by considering an entire series of
arrays in a single statistical model. The good performance of the
MAS5 algorithm has been noted by others [34].
Overall, if we had to choose a single preprocessing algorithm,
we would choose PLIER+16. However, several other algorithms
performed in a comparable manner. Ultimately, it is likely that
any of the top algorithms would be suitable for most purposes.
Materials and Methods
Samples
36 colon biopsies were taken during routine endoscopical
intervention before treatment at the 2nd Department of Internal
Medicine at the Semmelweis University Budapest and have been
described previously [11]. The biopsies were classified as adenoma
with (n = 6) or without dysplasia (n = 6), ulcerative colitis (n = 7),
Crohn’s disease (n = 1), colon cancer Dukes B (n= 6), colon cancer
Dukes C-D (n = 5) and normal tissue (n = 5). 29 human cancer cell
lines representing various cancer types were cultured under
identical conditions and collected during logarithmic growth
phase and have been described previously [12].
At the beginning of sample collection the written informed
consent of patients was obtained for the use of their samples for
diagnostic and scientific purposes. At the beginning of data
processing all samples received a unique three digit number, and
during further analyses this number was used without referring to
the patient’s name. The ethical committee of the Semmelweis
University approved the study; the study conformed to the
principles outlined in the Declaration of Helsinki.
Measurements
Samples were profiled using HG-U133A or HG-U133 Plus 2.0
microarrays (Affymetrix, Santa Clara), and RT-PCR measure-
ments were made on TaqMan 96-well arrays (Applied Biosystems,
Foster City) as described [12]. Some of the genes on the TaqMan
arrays were selected to validate our previous microarray studies
and have been published earlier [12], while others were selected
based on published clinical associations (e.g. colon cancer
associated genes) or as normalization controls. One sample from
the cell line data set was identified as low-quality (based on a very
low number of genes detected as present on the microarray) and
was removed from further analysis. Nonetheless, we have made
the raw, unfiltered data sets publicly available in their entirety
(GEO accession numbers GSE4183 and GSE11812 for micro-
arrays; Dataset S1 and Dataset S2 for RT-PCR).
Identification of common genes
We identified the targets (gene symbol and Refseq accession
numbers) of the RT-PCR probes using online annotation provided
by the manufacturer (accessed May 23, 2008). We identified the
targets of the microarray probe sets using annotation files
downloaded from the manufacturer’s website (dated March 18,
2008). To find comparable sets of measurements made on both
platforms, we identified RT-PCR probes and microarray probe
sets that queried not only the same gene, but also the same set of
transcript isoforms as determined by Refseq accession numbers.
For several genes, multiple microarray probe sets matched an RT-
PCR probe; in this case we chose the probe set with the most
individual probes matching the queried gene, and if this criterion
was not sufficient to choose a single probe set, we arbitrarily chose
the first probe set from those matching the criteria. By this
procedure we identified 84 genes in the colon cancer data set and
75 genes in the cell line data set measured by both platforms
(Table S1). Only these genes were used to assess agreement
between platforms.
Data analysis
All analysis was performed using the R statistical environment
(www.R-project.org) with Bioconductor packages (www.biocon-
ductor.org). All calculations and comparisons were performed
using log2-transformed expression values; all preprocessing
algorithms except MAS5 and MBEI return such values by default.
RT-PCR log2 expression values are given as the negative of the CT
(threshold cycle). All results can be reproduced using the scripts
provided in Text S1.
Microarray Algorithms
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Supporting Information
Dataset S1 A tab-delimited text file containing raw RT-PCR
CT values for the cell line data set.
Found at: doi:10.1371/journal.pone.0005645.s001 (0.03 MB
TXT)
Dataset S2 A tab-delimited text file containing raw RT-PCR
CT values for the colon data set.
Found at: doi:10.1371/journal.pone.0005645.s002 (0.03 MB
TXT)
Table S1 An Excel spreadsheet listing the comparable RT-PCR
probes and microarray probe sets used in this study.
Found at: doi:10.1371/journal.pone.0005645.s003 (0.03 MB
XLS)
Text S1 A PDF document providing R code to reproduce the
analysis described in the manuscript.
Found at: doi:10.1371/journal.pone.0005645.s004 (0.32 MB
PDF)
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